Toward innovative veterinary nanoparticle vaccines

被引:4
|
作者
Sun, Meiqi [1 ]
Pratama, Aldryan Cristianto [1 ]
Qiu, He [1 ]
Liu, Zehui [1 ,4 ]
He, Fang [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Inst Prevent Vet Med, Coll Anim Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China
[2] Zhejiang Prov Key Lab Prevent Vet Med, Hangzhou 310058, Peoples R China
[3] ZJU Xinchang Joint Innovat Ctr, TianMu Lab, Gaochuang Hitech Pk, Xinchang 312500, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Cardiovasc Key Lab Zhejiang Prov, Hangzhou 310009, Zhejiang, Peoples R China
来源
ANIMAL DISEASES | 2024年 / 4卷 / 01期
关键词
Nanoparticles; Veterinary vaccine; Self-assembling protein nanoparticles (SAPNs); Virus-like nanoparticles (VLPs); Immune responses; Animal infectious diseases; Optimization strategies; VIRUS-LIKE PARTICLES; HEMORRHAGIC-DISEASE VIRUS; RESPIRATORY SYNDROME VIRUS; PORCINE PARVOVIRUS; DENDRITIC CELLS; PROTECTIVE IMMUNITY; TARGETED DELIVERY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HUMORAL IMMUNITY;
D O I
10.1186/s44149-024-00119-w
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Nanoparticles are significant for veterinary vaccine development because they are safer and more effective than conventional formulations. One promising area of research involves self-assembled protein nanoparticles (SAPNs), which have shown potential for enhancing antigen-presenting cell uptake, B-cell activation, and lymph node trafficking. Numerous nanovaccines have been utilized in veterinary medicine, including natural self-assembled protein nanoparticles, rationally designed self-assembled protein nanoparticles, animal virus-derived nanoparticles, bacteriophage-derived nanoparticles, and plant-derived nanoparticles, which will be discussed in this review. SAPN vaccines can produce robust cellular and humoral immune responses and have been shown to protect against various animal infectious diseases. This article attempts to summarize these diverse nanovaccine types and their recent research progress in the field of veterinary medicine. Furthermore, this paper highlights their disadvantages and methods for improving their immunogenicity.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Validation of potency tests for veterinary vaccines
    Bruckner, L
    PROGRESS IN THE REDUCTION, REFINEMENT AND REPLACEMENT OF ANIMAL EXPERIMENTATION, 2000, 31 : 987 - 989
  • [32] Veterinary vaccines and their use in developing countries
    Lubroth, J.
    Rweyemamu, M. M.
    Viljoen, G.
    Diallo, A.
    Dungu, B.
    Amafu, W.
    REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES, 2007, 26 (01): : 179 - 201
  • [33] DETERMINATION OF THE VISCOSITY AND DENSITY OF VETERINARY VACCINES
    Krasucka, Dorota M.
    Kos, Katarzyna
    Wozniak, Aneta D.
    Cybulski, Wojciech A.
    ACTA POLONIAE PHARMACEUTICA, 2014, 71 (06): : 1090 - 1094
  • [34] Plant Production of Veterinary Vaccines and Therapeutics
    Hammond, R. W.
    Nemchinov, L. G.
    PLANT-PRODUCED MICROBIAL VACCINES, 2009, 332 : 79 - 102
  • [35] A SURVEY OF MYCOPLASMA DETECTION IN VETERINARY VACCINES
    THORNTON, DH
    VACCINE, 1986, 4 (04) : 237 - 240
  • [36] Laboratories which produce veterinary vaccines
    Randall, DC
    REVUE SCIENTIFIQUE ET TECHNIQUE DE L OFFICE INTERNATIONAL DES EPIZOOTIES, 1998, 17 (02): : 568 - 577
  • [37] Working together on developing veterinary vaccines
    不详
    VETERINARY RECORD, 2016, 178 (08) : 185 - 185
  • [38] Veterinary vaccines against Toxoplasma gondii
    Innes, Elisabeth A.
    Bartley, Paul M.
    Maley, Stephen
    Katzer, Frank
    Buxton, David
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2009, 104 (02): : 246 - 251
  • [39] The European veterinary vaccines industry and market
    Zanker, S
    Verschueren, C
    FISH VACCINOLOGY, 1997, 90 : 471 - 471
  • [40] Experience with veterinary vaccines in warm climates
    Tulasne, JJ
    Lefevre, PC
    Blancou, J
    NEW APPROACHES TO STABILISATION OF VACCINES POTENCY, 1996, 87 : 33 - 42